Track topics on Twitter Track topics that are important to you
RATIONALE: AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- To assess the activity of MEK inhibitor AZD6244, in terms of progression-free survival rate for ≥ 6 months after initiating therapy or objective response rate, in patients with recurrent or persistent endometrial carcinoma.
- To determine the nature and degree of toxicity of this regimen in these patients as assessed by NCI CTCAE v3.0.
- To determine the duration of progression-free survival and overall survival of patients treated with this regimen.
- To explore the association between select biomarkers and response to MEK inhibitor AZD6244 (progression-free survival status > 6 months and objective tumor response), measures of clinical outcome (progression-free survival and overall survival), or disease status, including histologic cell type.
- To explore the relationship among a panel of biomarkers, including mutations and single nucleotide polymorphisms in BRAF, KRAS2, FGFR2, PI3KCA, AKT1, AKT2, AKT3, and PTEN as well as immunohistochemical expression of ERK, pERK, GSK3β, pGSK3β, PR-A, PR-B, pPR, ERα, ERβ, BRAF, KRAS, PTEN, EGFR, pEGFR, EGF, PELP1, and MTA1s.
OUTLINE: This is a multicenter study.
Patients receive oral MEK inhibitor AZD6244 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Blood and archived tumor tissue samples are collected for biomarker studies.
After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment
MEK inhibitor AZD6244, laboratory biomarker analysis
University of Colorado Cancer Center at UC Health Sciences Center
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:18:03-0400
RATIONALE: AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well AZD6244 works in treating p...
RATIONALE: AZD6244 may stop the growth of cancer by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II clinical trial is studying how well AZD6244 works in treati...
RATIONALE: AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well AZD624...
This phase II trial is studying how well AZD6244 works in treating patients with papillary thyroid cancer that did not respond to radioactive iodine. AZD6244 may stop the growth of tumor c...
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. AZD6244 may s...
The present study investigated the molecular mechanism by which the epidermal growth factor receptor (EGFR) inhibitor cetuximab enhances the antitumor activity of the mitogen-activated protein kinase ...
Improved methods for preoperative risk stratification in endometrial cancer are highly requested by gynecologists. Texture analysis is a method for quantification of heterogeneity in images, increasin...
Recent epidemiological studies have investigated the associations between the use of bisphosphonates and the development of endometrial cancer and ovarian cancer; these studies have shown controversia...
Several markers have been studied to predict the responsiveness of endometrial hyperplasia (EH) and early endometrial cancer (EEC) to progestin therapy. PTEN has played a major role in this field, alt...
To evaluate the Risk of Endometrial Cancer (REC) scoring system for the prediction of high and low probability of endometrial cancer (EC) in women with postmenopausal bleeding (PMB).
Neoplasms of the endometrial stroma that sometimes involve the MYOMETRIUM. These tumors contain cells that may closely or remotely resemble the normal stromal cells. Endometrial stromal neoplasms are divided into three categories: (1) benign stromal nodules; (2) low-grade stromal sarcoma, or endolymphatic stromal myosis; and (3) malignant endometrial stromal sarcoma (SARCOMA, ENDOMETRIAL STROMAL).
A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.
The extension of endometrial tissue (ENDOMETRIUM) into the MYOMETRIUM. It usually occurs in women in their reproductive years and may result in a diffusely enlarged uterus with ectopic and benign endometrial glands and stroma.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers) - Mouth cancer can develop on the lip, the tongue, the floor...